N-[4-[[[2-(dimethylamino)-7-methylquinazolin-4-yl]amino]methyl]phenyl]-1-[(2-fluorophenyl)methyl]piperidine-4-carboxamide | 1039735-34-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-[4-[[[2-(dimethylamino)-7-methylquinazolin-4-yl]amino]methyl]phenyl]-1-[(2-fluorophenyl)methyl]piperidine-4-carboxamide
• CAS: 1039735-34-6
• 化学式: C₃₁H₃₅FN₆O
• 分子量: 526.657
• InChiKey: YAPPCPXCPKDGIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  73.4
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  N-[4-({[2-(dimethylamino)-7-methylquinazolin-4-yl]amino}methyl)phenyl]piperidine-4-carboxamide 、 2-氟苯甲醛 在 sodium cyanoborohydride 、 zinc(II) chloride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 N-[4-[[[2-(dimethylamino)-7-methylquinazolin-4-yl]amino]methyl]phenyl]-1-[(2-fluorophenyl)methyl]piperidine-4-carboxamide
  参考文献：
  名称：

  2,4-Diamino-quinazolines as inhibitors of β-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer

  摘要：

  The synthesis and SAR of a series of 2,4-diamino-quinazoline derivatives as beta-catenin/Tcf-4 inhibitors are described. This series was developed by modifying the initial lead 1, which was identified by screening of our compound library and found to inhibit the beta-catenin/Tcf-4 pathway. Replacement of the biphenyl moiety in compound 1 with the N-phenylpiperidine-4-carboxamide chain as in 2, resulted in a number of new analogues, which are potent inhibitors of the beta-catenin/Tcf-4 pathway. Compound such as 16k exhibited good cellular potency, solubility, metabolic stability and oral bioavailability. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.070

文献信息

• AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
  申请人：VENKATESAN Aranapakam M.

  公开号：US20090004185A1

  公开（公告）日：2009-01-01

  The present invention relates to amino-substituted quinazoline derivatives as inhibitors of β-catenin/tcf-4 pathway, which can be useful in the treatment of cancer; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.

  本发明涉及氨基取代的喹唑啉衍生物，作为β-连环蛋白/TCF-4途径的抑制剂，可用于癌症治疗；涉及其制备方法；涉及包含它们的制药组合物；以及使用它们的方法。
• [EN] AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF ß-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS<br/>[FR] DÉRIVÉS DE QUINALOZINE SUBSTITUÉS PAR AMINO EN TANT QU'INHIBITEURS DE LA VOIE B-CATÉNINE/TCF-4 ET AGENTS DE TRAITEMENT DU CANCER
  申请人：WYETH CORP

  公开号：WO2008086462A2

  公开（公告）日：2008-07-17

  [EN] The present invention relates to amino-substituted quinazoline derivatives as inhibitors of ß-catenin/tcf-4 pathway, which can be useful in the treatment of cancer; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.
  [FR] L'invention concerne des dérivés de quinazoline substitués par amino en tant qu'inhibiteurs de voie b-caténine/TCF-4, qui peuvent être utiles dans le traitement du cancer ; des procédés pour leur préparation ; des compositions pharmaceutiques les renfermant ; et des procédés d'utilisation de ceux-ci.
• 2,4-Diamino-quinazolines as inhibitors of β-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer
  作者：Zecheng Chen、Aranapakam M. Venkatesan、Christoph M. Dehnhardt、Osvaldo Dos Santos、Efren Delos Santos、Semiramis Ayral-Kaloustian、Lei Chen、Yi Geng、Kim T. Arndt、Judy Lucas、Inder Chaudhary、Tarek S. Mansour

  DOI：10.1016/j.bmcl.2009.07.070

  日期：2009.9

  The synthesis and SAR of a series of 2,4-diamino-quinazoline derivatives as beta-catenin/Tcf-4 inhibitors are described. This series was developed by modifying the initial lead 1, which was identified by screening of our compound library and found to inhibit the beta-catenin/Tcf-4 pathway. Replacement of the biphenyl moiety in compound 1 with the N-phenylpiperidine-4-carboxamide chain as in 2, resulted in a number of new analogues, which are potent inhibitors of the beta-catenin/Tcf-4 pathway. Compound such as 16k exhibited good cellular potency, solubility, metabolic stability and oral bioavailability. (C) 2009 Elsevier Ltd. All rights reserved.